The biotech company Moderna expects to be ready to ship about 20 million doses of experimental coronavirus vaccine to the United States by the end of this year.
Company officials said that if late-stage clinical studies by drug developers in Massachusetts prove its effectiveness and are approved by the federal government, it will prepare to distribute the vaccine called mRNA-1273 nationwide.
“From a distribution perspective, we are ready,” Dr. Tal Zaks, Moderna’s chief medical officer, told investors on Thursday’s conference call. “We hope that mRNA-1
U.S. single-day coronary artery case with the highest hit rate
Moderna said it is “actively preparing” to launch its vaccine, which is one of four vaccines in a Phase III clinical trial in the United States. The company has recruited 30,000 researchers and said it may have enough data to seek emergency approval. Taken at the end of November.
In its third-quarter earnings report, Moderna stated that it has received more than $1.1 billion in vaccine deposits from governments around the world, including $600 million from the United States, which has agreed to purchase up to 500 million doses.
Chief Financial Officer David Meline said the company hopes to deliver on these promises by providing 500 million to 1 billion doses of the drug in 2021.
Click here to complete coronary artery coverage
But it all depends on the success of the vaccine’s Phase 3 trial and whether the US Food and Drug Administration finally approves the injection. When 53 study subjects developed symptomatic COVID-19 cases, Moderna plans to conduct the first analysis of the vaccine’s efficacy, which may clear the way for the company to seek emergency use authorization from the FBI.
“I believe that if we release the COVID-19 vaccine, then 2021 will be the most important turning point in Moderna’s history,” CEO Stéphane Bancel said in a statement.
Click More from The New York Post.